Creo Medical Group’s (LON: CREO) shares are down on Friday following the announcement that it has opened its United States headquarters at the Summit, Danbury, Connecticut, USA.
The AIM-listed medical device firm said the space is designed to support Creo’s global growth and focus in the key United States market.
The new headquarters has a learning centre and a fully equipped laboratory for clinical development and training purposes.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
Craig Gulliford, CEO of Creo, said: “We are delighted and proud to have opened our first United States facility, illustrating our commitment to growth and our focus on the key United States Market.
“These new premises will provide an excellent working environment for our United States team and a platform to attract further talent in this key region of the United States market.”
Despite the upbeat announcement, Creo’s share price is down 2.96% on Friday at 180.5p.
Should you invest in Creo Medical shares?
Creo Medical shares are traded on the London stock exchange’s AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Creo Medical shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies